JP2007302690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007302690A5 JP2007302690A5 JP2007186380A JP2007186380A JP2007302690A5 JP 2007302690 A5 JP2007302690 A5 JP 2007302690A5 JP 2007186380 A JP2007186380 A JP 2007186380A JP 2007186380 A JP2007186380 A JP 2007186380A JP 2007302690 A5 JP2007302690 A5 JP 2007302690A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition
- pharmaceutical composition
- weight
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 34
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 claims 20
- -1 N, N-disubstituted amino Chemical group 0.000 claims 13
- 239000003995 emulsifying agent Substances 0.000 claims 12
- 125000005908 glyceryl ester group Chemical group 0.000 claims 12
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims 12
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002634 lipophilic molecules Chemical class 0.000 claims 10
- 239000003961 penetration enhancing agent Substances 0.000 claims 10
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical group CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 claims 9
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims 8
- RXBQNMWIQKOSCS-UHFFFAOYSA-N (7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methanol Chemical compound C1C2C(C)(C)C1CC=C2CO RXBQNMWIQKOSCS-UHFFFAOYSA-N 0.000 claims 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 8
- 229920000161 Locust bean gum Polymers 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000004676 glycans Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 8
- 239000000711 locust bean gum Substances 0.000 claims 8
- 235000010420 locust bean gum Nutrition 0.000 claims 8
- 229920001282 polysaccharide Polymers 0.000 claims 8
- 239000005017 polysaccharide Substances 0.000 claims 8
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 6
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 6
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims 6
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 201000001881 impotence Diseases 0.000 claims 6
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229940113164 trimyristin Drugs 0.000 claims 6
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims 6
- 229940117972 triolein Drugs 0.000 claims 6
- 229920000926 Galactomannan Polymers 0.000 claims 4
- 229920002907 Guar gum Polymers 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- RXBQNMWIQKOSCS-RKDXNWHRSA-N Myrtenol Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2CO RXBQNMWIQKOSCS-RKDXNWHRSA-N 0.000 claims 4
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical group O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003205 fragrance Substances 0.000 claims 4
- 239000000665 guar gum Substances 0.000 claims 4
- 235000010417 guar gum Nutrition 0.000 claims 4
- 229960002154 guar gum Drugs 0.000 claims 4
- 239000003589 local anesthetic agent Substances 0.000 claims 4
- 229920000136 polysorbate Polymers 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- 230000000717 retained effect Effects 0.000 claims 4
- 239000008247 solid mixture Substances 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- NCXUNZWLEYGQAH-UHFFFAOYSA-N 1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C NCXUNZWLEYGQAH-UHFFFAOYSA-N 0.000 claims 2
- KTPHASGENPMMQK-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC(C)CN(C)C KTPHASGENPMMQK-UHFFFAOYSA-N 0.000 claims 2
- KIPQYJOLEGBNHQ-UHFFFAOYSA-N 1-(dimethylamino)propan-2-yl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)CN(C)C KIPQYJOLEGBNHQ-UHFFFAOYSA-N 0.000 claims 2
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 claims 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229940033357 isopropyl laurate Drugs 0.000 claims 2
- 229940074928 isopropyl myristate Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229920005862 polyol Polymers 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QCYOIFVBYZNUNW-UHFFFAOYSA-N 2-(dimethylazaniumyl)propanoate Chemical compound CN(C)C(C)C(O)=O QCYOIFVBYZNUNW-UHFFFAOYSA-N 0.000 claims 1
- IQNPKRUTUGGDEQ-UHFFFAOYSA-N CN(C)CCCCCCCCCCCCOC(C)=O Chemical compound CN(C)CCCCCCCCCCCCOC(C)=O IQNPKRUTUGGDEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000003445 sucroses Chemical class 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/480,738 US6323241B1 (en) | 2000-01-10 | 2000-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551477A Division JP2003519657A (ja) | 2000-01-10 | 2001-01-10 | プロスタグランジン組成物および男性勃起機能障害の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007302690A JP2007302690A (ja) | 2007-11-22 |
| JP2007302690A5 true JP2007302690A5 (enExample) | 2008-01-10 |
Family
ID=23909154
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551477A Pending JP2003519657A (ja) | 2000-01-10 | 2001-01-10 | プロスタグランジン組成物および男性勃起機能障害の処置法 |
| JP2007186380A Pending JP2007302690A (ja) | 2000-01-10 | 2007-07-18 | プロスタグランジン組成物および男性勃起機能障害の処置法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551477A Pending JP2003519657A (ja) | 2000-01-10 | 2001-01-10 | プロスタグランジン組成物および男性勃起機能障害の処置法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6323241B1 (enExample) |
| EP (1) | EP1255552B1 (enExample) |
| JP (2) | JP2003519657A (enExample) |
| KR (1) | KR100614361B1 (enExample) |
| CN (1) | CN1394140A (enExample) |
| AT (1) | ATE290383T1 (enExample) |
| AU (1) | AU760576C (enExample) |
| BE (1) | BE2014C001I2 (enExample) |
| BR (1) | BR0107478A (enExample) |
| CA (1) | CA2395217C (enExample) |
| DE (1) | DE60109274T2 (enExample) |
| ES (1) | ES2236245T3 (enExample) |
| HK (1) | HK1047700B (enExample) |
| HU (1) | HUP0204159A3 (enExample) |
| IL (2) | IL150306A0 (enExample) |
| MX (1) | MXPA02006758A (enExample) |
| PT (1) | PT1255552E (enExample) |
| TR (1) | TR200201769T2 (enExample) |
| WO (1) | WO2001051053A1 (enExample) |
| ZA (1) | ZA200205433B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
| US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| EA008720B1 (ru) * | 1998-12-10 | 2007-06-29 | Нексмед (Холдингс), Инк. | Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US20050004226A1 (en) * | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US20040110843A1 (en) * | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| AU2003209350A1 (en) | 2002-01-25 | 2003-09-02 | Modular Properties Ltd | Methods and compositions for treating male erectile dysfunction |
| US20090257956A1 (en) * | 2002-01-25 | 2009-10-15 | Ramsey Sallis | Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation |
| US20090035221A1 (en) * | 2002-01-25 | 2009-02-05 | Ramsey Sallis | Methods and Compositions for Treatment of Erectile Dysfunction |
| MXPA04007828A (es) * | 2002-02-15 | 2004-10-15 | Nexmed Holdings Inc | Composicion de prostaglandina para eltratamiento de la disfuncion erectil. |
| AU2003273291A1 (en) * | 2002-09-06 | 2004-03-29 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfuntion |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| EP1605913A2 (en) * | 2003-03-21 | 2005-12-21 | Nexmed (Holdings), Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
| MXPA05010069A (es) * | 2003-03-21 | 2005-11-23 | Nexmed Holdings Inc | Composiciones de prostaglandina para el tratamiento de la disfuncion erectil. |
| AU2004224329B2 (en) * | 2003-03-21 | 2009-07-09 | Nexmed (Holdings), Inc. | Compositions and methods for treatment of premature ejaculation |
| US20050009918A1 (en) * | 2003-04-02 | 2005-01-13 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods for the treatment of vasospasm |
| US20050159985A1 (en) * | 2003-11-21 | 2005-07-21 | Bertram Carl T. | System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| US7655659B2 (en) * | 2004-08-19 | 2010-02-02 | Applied Genetics Incorporated Dermatics | Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| PH12013501104A1 (en) * | 2010-12-02 | 2013-07-08 | Nexmed Holdings Inc | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate |
| CA2838109C (en) | 2011-04-07 | 2020-06-09 | Nexmed Holdings, Inc. | Topical semisolid prostaglandin e1 composition for treating raynaud's disease |
| US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
| CN113149982A (zh) | 2015-01-20 | 2021-07-23 | Xoc制药股份有限公司 | 麦角灵化合物及其用途 |
| BR112017015510A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo |
| EP3266458A1 (en) | 2016-07-05 | 2018-01-10 | Fagron B.V. | Method and composition and kit for treating erectile dysfunction |
| JP2020522504A (ja) | 2017-06-01 | 2020-07-30 | エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ | 多環式化合物およびそれらの用途 |
| USD1122263S1 (en) * | 2023-02-15 | 2026-04-14 | Amadeus S.A.S. | Display screen with animated graphical user interface |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2818855A (en) | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
| BE790840A (fr) | 1971-11-01 | 1973-04-30 | Upjohn Co | Solutions de medicaments instables et leur preparation |
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4254145A (en) | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
| US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| ES2124225T3 (es) | 1990-04-25 | 1999-02-01 | Vivus Inc | Tratamiento de la disfuncion erectil. |
| US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
| CA2215307A1 (en) | 1995-03-14 | 1996-09-19 | Vivus, Incorporated | Pharmaceutical compositions and kits for preventing erectile dysfunction |
| WO1999002147A1 (en) * | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
| JP2003525845A (ja) * | 1997-10-28 | 2003-09-02 | ヴィヴァス・インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 |
| US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6102849A (en) | 1999-04-03 | 2000-08-15 | Hakac; John R. | Non-surgical penile prosthesis |
-
2000
- 2000-01-10 US US09/480,738 patent/US6323241B1/en not_active Expired - Lifetime
-
2001
- 2001-01-10 JP JP2001551477A patent/JP2003519657A/ja active Pending
- 2001-01-10 ES ES01942300T patent/ES2236245T3/es not_active Expired - Lifetime
- 2001-01-10 AU AU29349/01A patent/AU760576C/en not_active Expired
- 2001-01-10 KR KR1020027008845A patent/KR100614361B1/ko not_active Expired - Lifetime
- 2001-01-10 MX MXPA02006758A patent/MXPA02006758A/es active IP Right Grant
- 2001-01-10 TR TR2002/01769T patent/TR200201769T2/xx unknown
- 2001-01-10 WO PCT/US2001/000852 patent/WO2001051053A1/en not_active Ceased
- 2001-01-10 HK HK02109079.3A patent/HK1047700B/en not_active IP Right Cessation
- 2001-01-10 IL IL15030601A patent/IL150306A0/xx active IP Right Grant
- 2001-01-10 CA CA002395217A patent/CA2395217C/en not_active Expired - Lifetime
- 2001-01-10 PT PT01942300T patent/PT1255552E/pt unknown
- 2001-01-10 EP EP01942300A patent/EP1255552B1/en not_active Expired - Lifetime
- 2001-01-10 AT AT01942300T patent/ATE290383T1/de active
- 2001-01-10 CN CN01803447A patent/CN1394140A/zh active Pending
- 2001-01-10 DE DE60109274T patent/DE60109274T2/de not_active Expired - Lifetime
- 2001-01-10 BR BR0107478-4A patent/BR0107478A/pt not_active Application Discontinuation
- 2001-01-10 HU HU0204159A patent/HUP0204159A3/hu active IP Right Revival
-
2002
- 2002-06-18 IL IL150306A patent/IL150306A/en unknown
- 2002-07-08 ZA ZA200205433A patent/ZA200205433B/xx unknown
-
2007
- 2007-07-18 JP JP2007186380A patent/JP2007302690A/ja active Pending
-
2014
- 2014-01-06 BE BE2014C001C patent/BE2014C001I2/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2213916T3 (es) | Un sistema de administracion transdermica de farmacos para un agente analgesico antiinflamatorio que comprende sal de dietilamonio de diclofenaco, y su metodo de fabricacion. | |
| JP5184341B2 (ja) | 外用の医薬組成物 | |
| US5807568A (en) | Enhanced delivery of topical compositions containing flurbiprofen | |
| JP2006520801A5 (enExample) | ||
| US6083996A (en) | Topical compositions for NSAI drug delivery | |
| ES2350806T3 (es) | Composición de gel para el tratamiento de micosis. | |
| EP0404807A1 (en) | DEPRENYLE FOR SYSTEMIC TRANSDERMAL ADMINISTRATION. | |
| CN102292068A (zh) | 双氯芬酸、卡马西平和苄达明的透皮递送 | |
| JP2006501172A (ja) | 非晶質医薬組成物を用いる経皮送達速度調節 | |
| JP2006518359A (ja) | 経皮または経粘膜投与用の医薬組成物 | |
| CA2625804A1 (fr) | Composition pharmaceutique a base d'un agent antimycotique morpholinique et d' un agent filmogene hydrosoluble pour application ungueale et peri-ungueale | |
| PT1210934E (pt) | Preparação de transportador farmacêutico aplicável a superfícies de mucosas | |
| JP2009540019A (ja) | 局所組成物 | |
| RU2587064C2 (ru) | Новая противогрибковая композиция | |
| JP2007531694A (ja) | 局所適用医薬組成物 | |
| HUE026619T2 (en) | Pharmaceutical combination for the treatment of pain | |
| RU2381794C2 (ru) | Содержащая амброксол композиция для местного применения | |
| JP2010513500A5 (enExample) | ||
| AU2025275318A1 (en) | Long-acting injectable formulations and use thereof | |
| JP3483148B2 (ja) | 経皮投与基剤組成物およびその薬剤組成物 | |
| CA2583876A1 (en) | A transmucosal veterinary composition comprising detomidine | |
| JP2022538505A5 (enExample) | ||
| EA007351B1 (ru) | Фармацевтическая композиция для чрескожной доставки физиологически активных агентов | |
| JP2008534644A5 (ja) | ２型糖尿病を治療または予防する組成物 | |
| CN103930105B (zh) | 2-(n,n-二甲基氨基)-丙酸十二烷基酯的活性对映体 |